Why Fabrinet Stock Just Plummeted

Fabrinet reported fiscal Q4 (ended June 26) adjusted EPS of $4.10 on revenue of $1.32B, topping Wall Street expectations, with revenue up ~45% YoY. Despite encouraging current-quarter guidance of adjusted EPS $4.10–$4.25 on $1.375B–$1.425B revenue, free cash flow fell to -$36.9M due to high capex and full-year FCF to roughly $4M. The stock sank 19.4% in a session as investors focused on capex-driven FCF pressure.

Analysis

The market is treating this as a quality-of-earnings problem, not a growth problem. That matters because the first-order hit is to multiple rather than revenue: when a manufacturer posts strong top-line growth but burns cash to fund capacity, investors tend to re-rate it from “growth compounder” toward “capital-intensive cyclical,” and that compression can persist for 1-3 quarters even if demand stays intact. The immediate loser is FN’s valuation; the second-order winners are capital-light peers that can show similar end-demand exposure with cleaner free-cash-flow conversion, especially CLS, JBL, and SANM on a relative basis.

The key catalyst path is not next quarter’s EPS, but whether capex falls back into a maintenance range after the current buildout. If management can show FCF turning positive again over the next 1-2 reporting cycles, this drawdown is likely a de-risking event rather than the start of a structural de-rating. The bearish case only compounds if orders slow at the same time capex stays elevated, because then investors will assume the company is funding capacity into a decelerating demand curve and will pressure both the equity multiple and future buyback optionality.

Contrarian view: the market may be conflating temporary growth investment with permanent cash burn. In an AI/optics supply chain, capacity often arrives ahead of revenue, so negative FCF can be the price of securing future share; if that is the case, the current selloff can reverse quickly once capex peaks. The cleanest way to express that view is relative value rather than outright directional risk, because the stock can stay cheap longer than the operating story stays wrong.

Key Decisions for Investors

• Avoid chasing the move lower in FN immediately; wait 1-2 weeks for post-earnings positioning to clear and for management commentary on FY27 capex cadence before deciding whether the selloff is a buying opportunity.
• Pair trade: short FN / long CLS or JBL for 1-3 months. Thesis: if end-demand is fine, the market should reward better FCF conversion and punish FN’s heavier reinvestment burden; risk/reward is attractive if FN’s multiple compresses faster than peers.
• If already long FN, hedge with a 1-2 month put spread rather than selling core exposure; the near-term risk is continued de-rating on cash conversion, but upside can reappear quickly if capex normalizes.
• Set a thesis-falsification alert on next-quarter free cash flow and capex: if FCF remains negative despite revenue growth, assume the market will keep discounting the stock; if FCF turns positive again, the drawdown likely becomes a tactical entry point.
• Watch for relative strength in capital-light comp names versus FN over the next 4-6 weeks; a persistent spread would confirm the market is repricing balance-sheet efficiency, not just reacting to one noisy quarter.